Cybin Inc (HELP.NE) stock: key figures, P/E, revenue and dividend
Health Care · Canada · ISIN CA23256X4075
Cybin Inc financials
| Fiscal year | 2024 |
|---|---|
| Net income | -78.08 m CAD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cybin Inc
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
More stocks
- Bravo Multinational Inc. (BRVO)
- OLENOX INDUSTRIES INC. (OLOX)
- Fortune Valley Treasures, Inc. (FVTI)
- Nexentis Technologies Inc. (NXTS)
- Presidio Property Trust, Inc. (SQFT)
- Matinas BioPharma Holdings, Inc. (MTNB)
- HEALTHY CHOICE WELLNESS CORP. (HCWC)
- ORAGENICS INC (OGEN)
- Kaya Holdings, Inc. (KAYS)
- Adagio Medical Holdings, Inc. (ADGM)
- GPO Plus, Inc. (GPOX)
- Ocean Thermal Energy Corp (CPWR)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.